Terminated PHASE2 INTERVENTIONAL 2-arm NCT02415608

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis

Sponsor: Jason Robert Gotlib

Conditions Aggressive Systemic Mastocytosis Mast Cell Leukemia Systemic Mastocytosis

Interventions Ibrutinib

Updated 10 times since 2017 Last updated: Aug 24, 2018 Started: Mar 31, 2015 Primary completion: Nov 4, 2016 Completion: Jun 14, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Listed as NCT02415608, this PHASE2 trial focuses on Aggressive Systemic Mastocytosis and Mast Cell Leukemia and remains terminated or withdrawn. Sponsored by Jason Robert Gotlib, it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 5 earlier versions

Oct 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Oct 2018 [monthly]

Terminated PHASE2
Dec 2017 — Jun 2018 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Feb 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jason Robert Gotlib
National Cancer Institute (NCI)

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States